A single-arm, open-label, phase II trial of BXCL701, an oral innate immune activator, in combination with Keytruda (pembrolizumab) in patients with small cell neuroendocrine prostate cancer showed positive overall survival data. As of a data cutoff of Sept. 6, evaluable patients with SCNC showed a median OS of 13.6 months, and a 12-month survival rate of 56.5%.
TD Bank has committed $100,000 to support the MUSC Hollings Cancer Center’s SC AMEN program, a community outreach initiative that brings education, screenings, and health services assistance to Black men 40 to 69 years old in South Carolina.
